Amgen Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 14, 2023 / 03:40PM GMT
David Reed Risinger - SVB Securities LLC, Research Division - Senior MD

Great. So good morning, everyone. Thank you for joining us for this next session with Amgen. It's very much my pleasure on behalf of SVB Securities to host a few of the company's executives.

For those of you who don't know me, I'm Dave Risinger. I cover diversified biopharmaceuticals. And with us today, we have Peter Griffith, who's Executive Vice President and CFO; Susan Sweeney, who's Senior Vice President of Global Marketing Access and Capabilities; and Arvind Sood, who's Vice President of Investor Relations.

I thought it would be great, Peter, to turn it over to you to have you start us off with a few minutes of opening comments to frame the broader picture for Amgen before we transition to discussing some of the commercial opportunities with Susan.

So with that, let me turn it to you, Peter.

Peter H. Griffith - Amgen Inc. - Executive VP & CFO

Dave, thank you very much. Thank you, SVB Securities. We're always very pleased to join you. So we always started

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot